GeneReach Biotechnology Corp. Stock price

Equities

4171

TW0004171004

Pharmaceuticals

End-of-day quote Taipei Exchange 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
33.65 TWD +0.15% Intraday chart for GeneReach Biotechnology Corp. -1.03% -14.70%
Sales 2021 1.01B 31.66M Sales 2022 750M 23.46M Capitalization 3.03B 94.91M
Net income 2021 377M 11.79M Net income 2022 221M 6.91M EV / Sales 2021 3.46 x
Net cash position 2021 294M 9.19M Net cash position 2022 359M 11.22M EV / Sales 2022 3.57 x
P/E ratio 2021
10.3 x
P/E ratio 2022
14.1 x
Employees -
Yield 2021
5.51%
Yield 2022
2.27%
Free-Float 67.66%
More Fundamentals * Assessed data
Dynamic Chart
GeneReach Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GeneReach Biotechnology Corp.(TPEX:4171) dropped from S&P Global BMI Index CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GeneReach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Taiwan's OBI Pharma Grants Experimental Drug Rights to Odeon Therapeutics (Hong Kong) MT
GeneReach Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Genereach Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Genereach Biotechnology Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 day+0.15%
1 week-1.03%
Current month-11.56%
1 month-11.68%
3 months-13.72%
6 months-0.88%
Current year-14.70%
More quotes
1 week
33.50
Extreme 33.5
34.50
1 month
33.50
Extreme 33.5
38.60
Current year
33.50
Extreme 33.5
42.80
1 year
30.45
Extreme 30.45
49.84
3 years
30.45
Extreme 30.45
137.45
5 years
26.14
Extreme 26.1381
307.30
10 years
11.13
Extreme 11.1264
307.30
More quotes
Managers TitleAgeSince
Chief Executive Officer - 10-08-31
Founder - 04-11-11
Director of Finance/CFO - 15-08-09
Members of the board TitleAgeSince
Founder - 04-11-11
Chief Executive Officer - 10-08-31
Director/Board Member - 04-12-31
More insiders
Date Price Change Volume
24-03-28 33.65 +0.15% 59,094
24-03-27 33.6 +0.30% 129,813
24-03-26 33.5 -1.76% 89,636
24-03-25 34.1 +1.19% 76,996
24-03-22 33.7 -0.88% 132,784

End-of-day quote Taipei Exchange, March 27, 2024

More quotes
GeneReach Biotechnology Corp. is principally engaged in the manufacture and distribution of animal testing equipment and testing agents. The Company mainly operates through Taiwan segment. The Company provides shrimp virus testing agents, on-site detection systems for fish and shrimp, mini centrifugal machines, pet disease testing agents and other testing equipment.
More about the company
  1. Stock
  2. Equities
  3. Stock GeneReach Biotechnology Corp. - Taipei Exchange